Indication

Human Papillomavirus Type 18 Infection

1 clinical trial

1 product

Clinical trial

An Open-Label, Phase 1/2 Study to Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of RG002 Injection (an mRNA Therapeutic Vaccine) in Subjects With Human Papillomavirus (HPV) 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3 (CIN2/3)

Status: Not yet recruiting, Estimated PCD: 2026-10-01

Product